Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 8Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrence × Aclarubicin × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡